Abbott has unveiled its new insertable cardiac monitor (ICM), Jot Dx, in the US to enhance precise diagnosis of abnormal heart rhythms, which are hard to detect, and lower data burden.
To aid doctors and hospitals in managing the data flow, the Jot Dx ICM has a feature to see either all abnormal heart rhythm information or select the irregular heart rhythms to be recorded using a ‘key episodes’ option.
This technology facilitates the detection of cardiac arrhythmia remotely and enhances the preciseness of patient diagnosis.
Arrhythmia is an irregular heart rhythm that occurs in cases when disease or injury disturbs the electrical signals of the heart, leading to an erratic heartbeat.
Jot Dx ICM tracks the cardiac rhythms of patients continuously. The device can be directly connected through Bluetooth to a mobile app, myMerlin, which can send data to doctors and patients in real time.
Abbott noted that this is the first time an ICM is offering improved control over patient monitoring, with an option to check three vital episodes or all episodes based on patients’ requirements. Furthermore, such functionality lowers the overall data burden.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
Jot Dx ICM is supported by a customised service, SyncUP, which offers one-on-one training and instruction to assist patients who are using the ICM.
After connection to Jot, doctors can remotely observe patients, enabling the detection of asymptomatic episodes and patient-triggered transmissions to offer quicker intervention.
In addition, remote monitoring can reduce the time for diagnosis and care decisions.
Abbott cardiac rhythm management business global clinical and regulatory divisional vice-president Heidi Hinrichs said: “Technology can be intimidating, particularly when your heart is relying on it.
“With Jot Dx ICM, myMerlin, SyncUP and our other technologies, we want people to feel supported, knowledgeable and confident when using them, and ultimately, in control of their care.”
Last week Abbott reported sales of $10.2bn for the Q2 of 2021, as against $7.32bn in the Q2 last year, up 39.5% on a reported basis and 35% on an organic basis.